Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions

Greenwich LifeSciences, Inc.

Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).
Company reports interest from large pharma, regional pharma, and biotech investors regarding licensing and collaboration.
Discussions include possible GP2 licensing, new investment banking partners, Phase III trial collaboration, and European expansion.
GP2 treatment was well tolerated with no serious adverse events across 138 patients in 4 clinical trials.
Phase III clinical trial planned with similar treatment regime to Phase IIb.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.